Search
for
Sort by
Research 181–210 of 1000+
- LB1029 The common fragrance, linalool, promotes core hair follicle pathology events associated with frontal fibrosing alopecia through activating a cognate olfactory receptor in the bulge
- 058 The pattern of Fas and Fas ligand expression in alopecia areata
- Association between hemoglobin A1c and the severity of androgenetic alopecia among female patients in a specialty alopecia clinic
- Efficacy of Low-Dose Spironolactone for Hair Loss in Women.
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- What is Alopecia?
- Response to Bhoyrul B., “The treatment of primary cicatricial alopecia is challenging”
- Patient satisfaction with multidisciplinary shared medical appointments for alopecia areata and frontal fibrosing alopecia
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Platelet-Rich Plasma for Androgenetic Alopecia: What the Dermatologist Needs to Know
- 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib
- 41949 Raman spectroscopy of alopecia drugs to assess their potential for laser-assisted drug delivery
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Treatment modalities for lymphocytic and neutrophilic scarring alopecia
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Use of supplements for hair loss in skin of color patients
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Androgenetic Alopecia: Therapy Update
- Complementary and alternative medicine for hair loss
- ISID0197 - Quantitative analysis of hair loss in mice utilizing imageJ improves the efficacy evaluation of alopecia areata induction in the C3H/HeJ mouse model
- 1406 Environmental pathobiology of frontal fibrosing alopecia (FFA): A link between linalool sensitization and FFA development
- 667 Patient satisfaction with a multidisciplinary alopecia areata group medical visit
- 197 Quantitative analysis of hair loss in mice utilizing imageJ improves the efficacy evaluation of alopecia areata induction in the C3H/HeJ mouse model
- Response to Weinstein’s “Reply of Increased risk of vitamin D deficiency and insufficiency in Black patients with central centrifugal cicatricial alopecia.”
- Alopecia areata incognita: clinical characteristics and use of the Sinclair shedding scale